Should I buy or sell Janux Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JANX shares. View JANX analyst ratings or view top-rated stocks .

What is Janux Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 12-month price objectives for Janux Therapeutics' shares. Their JANX share price targets range from $35.00 to $100.00. On average, they anticipate the company's stock price to reach $61.33 in the next year. This suggests a possible upside of 23.3% from the stock's current price. View analysts price targets for JANX or view top-rated stocks among Wall Street analysts .

How have JANX shares performed in 2024?

Janux Therapeutics' stock was trading at $10.73 at the beginning of 2024. Since then, JANX shares have increased by 363.6% and is now trading at $49.74. View the best growth stocks for 2024 here .

Are investors shorting Janux Therapeutics?

Janux Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,750,000 shares, an increase of 20.6% from the March 15th total of 3,110,000 shares. Based on an average daily volume of 711,600 shares, the days-to-cover ratio is currently 5.3 days. Currently, 11.6% of the company's stock are short sold. View Janux Therapeutics' Short Interest .

When is Janux Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our JANX earnings forecast .

How were Janux Therapeutics' earnings last quarter?

Janux Therapeutics, Inc. (NASDAQ:JANX) posted its quarterly earnings results on Friday, March, 8th. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.12. The business earned $2.46 million during the quarter, compared to the consensus estimate of $0.98 million. Janux Therapeutics had a negative net margin of 721.18% and a negative trailing twelve-month return on equity of 17.88%.

What ETFs hold Janux Therapeutics' stock?

ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . Fidelity Disruptive Medicine ETF (FMED) .

When did Janux Therapeutics IPO?

Janux Therapeutics (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

How do I buy shares of Janux Therapeutics?

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:JANX

Janux Therapeutics (JANX) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free JANX Stock Alerts

$48.71

+0.75 (+1.56%)

(As of 10:20 AM ET)

Compare

Today's Range: $47.32
▼
$48.86
50-Day Range: $7.93
▼
$52.65
52-Week Range: $5.65
▼
$58.69

Volume: 40,720 shs
Average Volume: 750,368 shs
Market Capitalization: $2.52 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $61.33

Get Janux Therapeutics alerts:

Janux Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 23.3% Upside
$61.33 Price Target
Short Interest: Bearish
11.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.52
Based on 16 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.41) to ($1.64) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

Medical Sector

628th out of 914 stocks

Pharmaceutical Preparations Industry

289th out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Janux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Janux Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
11.58% of the float of Janux Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Janux Therapeutics has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Janux Therapeutics has recently increased by 20.58%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Janux Therapeutics does not currently pay a dividend.
Dividend Growth
Janux Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JANX.

2.0

News and Social Media Coverage

News Sentiment
Janux Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Janux Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 36 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Janux Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Janux Therapeutics is -37.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Janux Therapeutics is -37.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Janux Therapeutics has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Janux Therapeutics Stock (NASDAQ:JANX)

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

JANX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JANX Stock News Headlines

April 17, 2024 | investorplace.com

Take the Money and Run: 3 Overbought Stocks to Sell ASAP

April 17, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - JANX

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 17, 2024 | americanbankingnews.com

Janux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at Jonestrading

April 16, 2024 | msn.com

JonesTrading Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation

April 16, 2024 | msn.com

Janux a new buy at Jones on lead assets for solid tumors

April 16, 2024 | investorplace.com

These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?

April 16, 2024 | benzinga.com

A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 15, 2024 | americanbankingnews.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Recommendation of "Buy" by Brokerages

April 13, 2024 | americanbankingnews.com

Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $44.62

April 12, 2024 | fool.com

Why Janux Therapeutics Stock Is Crushing It This Week

April 11, 2024 | theglobeandmail.com

Stocks See Continued Pressure as Bond Yields Climb

April 11, 2024 | benzinga.com

Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?

April 11, 2024 | finance.yahoo.com

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

April 11, 2024 | investors.com

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

April 10, 2024 | fool.com

Why Janux Therapeutics Stock Soared as the Market Sagged Today

April 10, 2024 | msn.com

Janux Therapeutics surges amid report of takeover interest

April 5, 2024 | morningstar.com

Janux Therapeutics Inc Ordinary Shares JANX

April 5, 2024 | nasdaq.com

Commit To Purchase Janux Therapeutics At $25, Earn 26.5% Annualized Using Options

March 20, 2024 | msn.com

Cantor starts Janux at overweight, cites TCE leadership position

March 20, 2024 | markets.businessinsider.com

Forecasting The Future: 4 Analyst Projections For Janux Therapeutics

March 20, 2024 | finance.yahoo.com

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst

March 20, 2024 | benzinga.com

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

March 15, 2024 | investorplace.com

JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023

March 15, 2024 | fool.com

2 Stocks That Have More Than Tripled This Year: Are They Buys?

March 14, 2024 | markets.businessinsider.com

Stranahan Recommends Buy on Janux Therapeutics with Increased Price Objective Amid Promising Drug Advances

See More Headlines

Receive JANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/08/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:JANX
CUSIP: N/A
CIK: 1817713
Web: www.januxrx.com
Phone: 858-751-4493
Fax: N/A
Employees: 64
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $61.33
High Stock Price Target: $100.00
Low Stock Price Target: $35.00
Potential Upside/Downside: +27.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,290,000.00
Net Margins: -721.18%
Pretax Margin: -721.18%
Return on Equity: -17.88%
Return on Assets: -15.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 26.80
Quick Ratio: 26.80

Sales & Book Value

Annual Sales: $8.08 million
Price / Sales: 306.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.46 per share
Price / Book: 6.43

Miscellaneous

Outstanding Shares: 51,660,000
Free Float: 33,372,000
Market Cap: $2.48 billion
Optionable: Optionable
Beta: 4.18

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. David Alan Campbell Ph.D. (Age 64)
President, CEO & Director
Comp: $852.5k
Mr. Byron Robinson J.D. (Age 59)
Ph.D., Chief Strategy Officer
Comp: $606.8k
Mr. Tighe M. Reardon C.F.A. (Age 47)
CPA, Acting Chief Financial Officer
Mr. Charles M. Winter (Age 55)
Chief Technical Officer
Dr. Tommy Diraimondo Ph.D.
Chief Scientific Officer
Mr. James Pennington
General Counsel
Ms. Brenda Van Vreeswyk
Head of Human Resources
Mr. Andy Hollman Meyer (Age 40)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JANX Stock Analysis - Frequently Asked Questions

Should I buy or sell Janux Therapeutics stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JANX shares.
View JANX analyst ratings or view top-rated stocks.
What is Janux Therapeutics' stock price target for 2024?: 7 Wall Street research analysts have issued 12-month price objectives for Janux Therapeutics' shares. Their JANX share price targets range from $35.00 to $100.00. On average, they anticipate the company's stock price to reach $61.33 in the next year. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for JANX or view top-rated stocks among Wall Street analysts.
How have JANX shares performed in 2024?: Janux Therapeutics' stock was trading at $10.73 at the beginning of 2024. Since then, JANX shares have increased by 363.6% and is now trading at $49.74.
View the best growth stocks for 2024 here.
Are investors shorting Janux Therapeutics?: Janux Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,750,000 shares, an increase of 20.6% from the March 15th total of 3,110,000 shares. Based on an average daily volume of 711,600 shares, the days-to-cover ratio is currently 5.3 days. Currently, 11.6% of the company's stock are short sold.
View Janux Therapeutics' Short Interest.
When is Janux Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our JANX earnings forecast.

How were Janux Therapeutics' earnings last quarter?: Janux Therapeutics, Inc. (NASDAQ:JANX) posted its quarterly earnings results on Friday, March, 8th. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.12. The business earned $2.46 million during the quarter, compared to the consensus estimate of $0.98 million. Janux Therapeutics had a negative net margin of 721.18% and a negative trailing twelve-month return on equity of 17.88%.
What ETFs hold Janux Therapeutics' stock?: ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Fidelity Disruptive Medicine ETF (FMED).
When did Janux Therapeutics IPO?: Janux Therapeutics (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.
How do I buy shares of Janux Therapeutics?: Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JANX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Janux Therapeutics (JANX) Stock Price, News & Analysis

Janux Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Janux Therapeutics Stock (NASDAQ:JANX)

JANX Stock Price History

JANX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

JANX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™